Prostate Cancer Coverage from Every Angle

Insurance and Mortality in Prostate and Other Cancers

By: Melissa E. Fryman, MS
Posted: Wednesday, October 9, 2019

According to a population-based study by Alexander P. Cole, MD, of Harvard Medical School, and colleagues, cancer-specific mortality is higher for uninsured patients with prostate cancer, and other cancers, relative to those with health insurance. The study’s findings were published in the JNCCN–Journal of the National Comprehensive Cancer Network.

“Insurance coverage at the time of diagnosis is independently associated with reduced [cancer-specific mortality] among patients with ovarian, pancreatic, lung, colorectal, breast, and prostate cancers,” concluded the authors. “Understanding the strength of the association between insurance status and cancer outcomes has clear relevance given ongoing legislative debates about policies, which have the potential to alter insurance rates.”

In this study, the insurance status and cancer-specific mortality rates of patients with cancer (representing about 26% of the U.S. population) were obtained from the Surveillance, Epidemiology, and End Results database. Overall, 97% of patients with prostate cancer included in the analysis had insurance; insured individuals had higher income and educational levels, were more likely to be married, and were less likely to be black.

In the combined cohort of 332,703 patients with cancer, no insurance coverage was associated with worse overall cancer-specific mortality (P < .0001). After the investigators adjusted for disease stage at diagnosis, the adjusted hazard ratio for uninsured patients with prostate cancer improved from 2.98 to 1.33.

“Insurance coverage has the largest magnitude of association with breast and prostate cancers…. In contrast, insurance coverage conferred a less pronounced benefit in ovarian and pancreatic cancers,” concluded the authors. “Our results are consistent with a large portion of the benefit of insurance coverage arising from detection and treatment of prevalent, but curable, early-stage cancers.”

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.